Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc. (SUPN)
Filing Type: Form 8-K (Current Report)
Date of Report: August 8, 2023
Reporting Period: Second quarter ended June 30, 2023
Context: This filing announces the issuance of a press release regarding Q2 2023 financial results and schedules a conference call for August 8, 2023.
Key Financial Metrics
The provided text is a cover report referencing a press release (Exhibit 99.1) but does not contain specific financial data tables or figures.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Material Changes
The filing text does not provide specific numerical comparisons or material changes versus the prior comparable period. It only confirms that results for the second quarter ended June 30, 2023, have been issued.
Guidance, Outlook, and Risks
Management Commentary: The company hosted a conference call and webcast to present business and financial results. The webcast was archived for 60 days.
Forward-Looking Statements: The filing contains forward-looking statements regarding plans, strategies, and intentions. These are subject to risks and uncertainties, including those detailed in the Risk Factors section of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022.
Legal Disclaimer: Information furnished under Item 2.02 and Item 9.01 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2023 revenue, net income, and cash flow figures.
- Access the archived webcast on the company website for management's detailed commentary on the results.
- Consult the Form 10-K for the fiscal year ended December 31, 2022, to understand the specific risk factors referenced in this filing.
- Verify the company's liquidity position and debt obligations in the full quarterly report (Form 10-Q) rather than this summary 8-K.